Follow Us GraphicFacebook IconTwitter IconLinkedIn Icon
Search Graphic

Expert Financial Analysis and Reporting

Tag archive for ‘Neuralstem, Inc.’

Notes from Neuralstem Presentation at Biotech Showcase Conference, January 13, 2015 (CUR, Buy, $3.09)

Richard Gar, CEO of Neuralstem (CUR), made a presentation at Biotech Showcase Conference in San Francisco on January 13, 2015. So far, everything seems to be trending positively in the trials. The Company is roughly on schedule with its clinical trials that are currently ongoing in four different disease states. The NSI-566 neural stem cells […]

Neuralstem: An Update on Potential Catalysts for 2015 (CUR, Buy, 3.38)

Overview and Investment Thinking I wrote a report on Neuralstem on August 26, 2014 in which I projected the timing of important investment catalysts for 2015. This is an update of that report although there have been no significant changes since then. I think that the phase 2a data from the trial of the Company’s NSI-566 […]

Neuralstem: Some Encouraging, But Very Early, Information on Chinese Ischemic Stroke Trial Using NSI-566 Stem Cells (CUR, Buy, $2.59)

Purpose of This Blog I received this e-mail communication from a SmithOnStocks subscriber who has a good insight into the Chinese drug market and drug development. This is the first report of any kind that I have seen on patient outcomes in the trial of Neuralstem’s Chinese trial of NSI-566 stem cells in ischemic stroke […]

Weakness in Neuralstem Caused by Seeking Alpha Article Presents a Buying Opportunity (CUR, $2.69, Buy)

This is an updated version of a blog that was published on October 20th. A Seeking Alpha article on results from a phase 2a trial of GM 640, a drug being developed by the privately held company Genervon, led to an unwarranted sharp decline in the price of Neuralstem. SA failed to understand that this […]

Neuralstem: Previewing Upcoming Important Events and Some Thoughts on the StemCell Patent Infringement Lawsuit (CUR, $3.62 Buy, August 26, 2014)

Key Points The phase 2 trial of NSI-566 in 15 ALS patients has completed enrollment (surgeries) and final topline data could be available in 1Q, 2015. However, there may be some interim data released at the ANA meeting during October 12 through 14. If the phase 2 data is compelling, it raises the possibility of […]

Neuralstem: Phase 1b Results for NSI-189 are Very Encouraging but It Is Early Days (CUR, Buy, $4.38, For paid subscribers)

Investment Thesis on Neuralstem I continue with my long standing buy on Neuralstem that is almost entirely based on the potential for its neural stem cell product NSI-566 in the treatment of ALS. Recently, encouraging phase 1b results have been reported for the small molecule drug NSI-189 in the treatment of major depressive disorder. These […]

Neuralstem: Encouraging Phase 1b Data on NSI-189 (CUR, Buy, $4.35, Free content)

On June 17 at the American Society of Clinical Psychopharmacology Neuralstem reported phase 1b data for its small molecule drug NSI-189 in a randomized double blind trial in depression. This involved 6 patients on placebo and 6 patients on each of three different dosing regimens for a total of 24 patients. The study ran for […]

Neuralstem: An In-Depth Look at NSI-189, A Novel Small Molecule Drug Being Studied in Major Depressive Disorder (CUR, Buy, $3.60, For Paid Subscribers)

Investment Thesis My recommendation of Neuralstem (CUR) has been based primarily on the potential for its neural stem cells NSI-566 in treating ALS. However, the Company is also developing NSI-189, a novel small molecule drug that could offer a completely new approach to treating major depressive disorder and other central nervous system diseases. Drug research […]

Thoughts on the Market Correction in Biotechnology Stocks

This Has Been a Tough Correction The recent sharp market correction and rotation out of growth stocks like biotechnology and technology has had a major impact on the small biotechnology names that I specialize in. The correction has been stomach churning for me even though I have been through this many times before. I am […]

Neuralstem: Dr. Eva Feldman’s Latest Presentation on The Use of CUR’s Stem Cells in ALS (CUR, Buy, $4.04)

Overview Dr. Eva Feldman is the lead investigator for the clinical trials of Neuralstem’s (CUR) NSI-566 spinal cord stem cells in the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease). She spoke at the Keystone Symposia on April 9, 2014. Dr. Feldman is the recent President of the American Neurological Association. She is […]